BioRestorative Therapies (BRTX) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to -$3.7 million.
- BioRestorative Therapies' Income towards Parent Company fell 6217.85% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.5 million, marking a year-over-year decrease of 2007.52%. This contributed to the annual value of -$11.6 million for FY2024, which is 2408.27% up from last year.
- Latest data reveals that BioRestorative Therapies reported Income towards Parent Company of -$3.7 million as of Q3 2025, which was down 6217.85% from -$3.3 million recorded in Q2 2025.
- Over the past 5 years, BioRestorative Therapies' Income towards Parent Company peaked at -$2.3 million during Q3 2024, and registered a low of -$15.1 million during Q1 2021.
- Its 5-year average for Income towards Parent Company is -$4.4 million, with a median of -$4.0 million in 2021.
- In the last 5 years, BioRestorative Therapies' Income towards Parent Company tumbled by 173820.0% in 2021 and then soared by 6643.04% in 2022.
- Quarter analysis of 5 years shows BioRestorative Therapies' Income towards Parent Company stood at -$4.0 million in 2021, then decreased by 16.78% to -$4.7 million in 2022, then surged by 31.21% to -$3.2 million in 2023, then increased by 16.47% to -$2.7 million in 2024, then plummeted by 37.87% to -$3.7 million in 2025.
- Its last three reported values are -$3.7 million in Q3 2025, -$3.3 million for Q2 2025, and -$4.8 million during Q1 2025.